JPH06279256A - Skin external preparation - Google Patents

Skin external preparation

Info

Publication number
JPH06279256A
JPH06279256A JP5071296A JP7129693A JPH06279256A JP H06279256 A JPH06279256 A JP H06279256A JP 5071296 A JP5071296 A JP 5071296A JP 7129693 A JP7129693 A JP 7129693A JP H06279256 A JPH06279256 A JP H06279256A
Authority
JP
Japan
Prior art keywords
skin
bacteria
external preparation
radix
fructus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP5071296A
Other languages
Japanese (ja)
Inventor
Yoshinori Nakayama
美紀 中山
Norikazu Ikeda
紀和 池田
Takayoshi Kato
敬香 加藤
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CLUB KOSUMECHITSUKUSU KK
Original Assignee
CLUB KOSUMECHITSUKUSU KK
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by CLUB KOSUMECHITSUKUSU KK filed Critical CLUB KOSUMECHITSUKUSU KK
Priority to JP5071296A priority Critical patent/JPH06279256A/en
Publication of JPH06279256A publication Critical patent/JPH06279256A/en
Pending legal-status Critical Current

Links

Landscapes

  • Medicinal Preparation (AREA)
  • Cosmetics (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

PURPOSE:To obtain a skin external preparation capable of keeping the balance of dermal indigenous bacteria, preventing common acne and skin roughening and aiming at the maintenance of the healthy skin by bending weakly acidic galenical extracts having antimicrobial activity against the dermal indigenous bacteria. CONSTITUTION:This skin external preparation comprises at least one galenical extract selected from Hydrangeae Dulcis Folium, Sanguisorbae Rhizoma, Sophorae Radix, Sophorae Flos, Schizandrae Fructus, Phellodendri Cortex, Coptidis Rhizoma, Pseudocydoniae Fructus, Rosae Fructus, Prunellae Spica, Paeoniae Radix, Saposhnikoviae Radix and Moutan Cortex.

Description

【発明の詳細な説明】Detailed Description of the Invention

【0001】[0001]

【産業上の利用分野】本発明は皮膚常在菌のバランスを
保ち、健康な皮膚を維持するために、皮膚常在菌に対
し、弱酸性条件下で強い又は穏やかな抗菌作用を有する
特定の生薬抽出物を含有する皮膚外用剤に関する。
BACKGROUND OF THE INVENTION The present invention has a specific antibacterial action against mild skin acidic bacteria under mildly acidic conditions in order to maintain the balance of normal bacterial skin and maintain healthy skin. The present invention relates to a skin external preparation containing a crude drug extract.

【0002】[0002]

【従来の技術】一般に、ヒト皮膚上には多種の微生物が
常在して微生物叢を形成し、皮膚の恒常性を保つ一因と
なっていると言われている。皮膚常在微生物には、主と
して、プロピオニバクテリウム アクネス (Prop
ionibacteriumacnes)等のプロピオ
ニバクテリウム属細菌、黄色ブドウ球菌と呼ばれるスタ
フィロコッカス アウレウス(Staphylococ
cus aureus)、および、表皮ブドウ球菌と呼
ばれるスタフィロコッカス エピデルミディス(Sta
phylococcus epidermidis)等
のスタフィロコッカス属細菌があり、その他ミクロコッ
カス属の細菌等、多種の微生物が存在している。これら
の微生物は皮膚上でバリアーとして働いている反面、過
度の増殖によりニキビや炎症など皮膚疾患の原因となる
ことが知られている。
2. Description of the Related Art Generally, it is said that various kinds of microorganisms are resident on human skin to form a microflora, which is one of the factors for maintaining the homeostasis of the skin. The skin-resident microorganisms are mainly Propionibacterium acnes (Prop
Propionibacterium, such as Ionibacterium, and Staphylococcus aureus called Staphylococcus aureus
cus aureus) and Staphylococcus epidermidis called Staphylococcus epidermidis (Sta
There are Staphylococcus bacteria such as phylococcus epidermidis) and various other microorganisms such as Micrococcus bacteria. While these microorganisms act as a barrier on the skin, it is known that excessive proliferation causes skin diseases such as acne and inflammation.

【0003】皮膚上では皮脂分泌亢進により皮脂貯留が
おこり、皮膚に常在する微生物が増加する。それにとも
なう細菌性リパーゼの増加により、皮脂成分であるトリ
グリセライドが分解され、遊離脂肪酸が増加し炎症を引
き起こすと言われている。このような働きをするリパー
ゼは、嫌気性細菌であるプロピオニバクテリウム アク
ネス(Propionibacterium acne
s)だけでなく、コアグラーゼ陰性ブドウ球菌である表
皮ブドウ球菌(Staphylococcusepid
ermidis)にも存在している事が知られており、
(皮膚,10,585,1969)トリグリセライドを
分解することも明らかにされている。(J.inves
t.derm.53,1,1969)
Accumulation of sebum occurs on the skin due to increased sebum secretion, and the number of microorganisms resident in the skin increases. It is said that due to the increase in bacterial lipase accompanying this, triglyceride which is a sebum component is decomposed and free fatty acids increase to cause inflammation. The lipase that functions in this way is Propionibacterium acnes, which is an anaerobic bacterium.
s) but also Staphylococcus epidermidis, a coagulase-negative staphylococcus
ermidis) is also known to exist,
(Skin, 10,585,1969) It has also been shown to degrade triglycerides. (J. Inves
t. derm. 53,1,1969)

【0004】従来このような皮膚の炎症を誘発する微生
物の増殖を抑制する目的で多くの薬剤が使用されてき
た。たとえば、テトラサイクリン、ペニシリン、エリス
ロマイシン、クロラムフェニコール等の抗生物質や殺菌
剤、抗菌剤と言われるものであるが、これらは、副作用
を有したり、皮膚上の有用微生物までも抑制し皮膚常在
菌の微妙なバランスをくずしてしまうという、いわゆる
エコロジーの観点から、時には好ましくない事態を引き
起こすことが指摘されている。
Conventionally, many drugs have been used for the purpose of suppressing the growth of such microorganisms that induce skin inflammation. For example, tetracycline, penicillin, erythromycin, chloramphenicol, and other antibiotics, bactericides, and antibacterial agents are known, but these have side effects and suppress even useful microorganisms on the skin, and they are commonly used in the skin. It has been pointed out that it sometimes causes an unfavorable situation from the viewpoint of so-called ecology, which destroys the delicate balance of the presence of bacteria.

【0005】近年、黄色ブドウ球菌や、これまで非病原
性の常在菌と考えられてきた表皮ブドウ球菌に代表され
るコアグラーゼ陰性ブドウ球菌が、弱毒菌感染の面やア
トピー性皮膚炎とのかかわりの面から注目されてくるよ
うになり、多くの症例の細菌叢に関する研究がなされて
いる。また、健常皮膚細菌叢に関してもいくつかの報告
があり、健常皮膚常在細菌の分布と肌質との関係も明ら
かにされており、皮膚微生物の制御の必要性が重視され
てきている。
In recent years, coagulase-negative staphylococci represented by Staphylococcus aureus and Staphylococcus epidermidis, which have been considered as non-pathogenic indigenous bacteria, are involved in the aspect of attenuated bacterium infection and atopic dermatitis. From the aspect of the above, attention has been paid to research on the bacterial flora in many cases. In addition, there have been some reports on the healthy skin flora, and the relationship between the distribution of healthy skin indigenous bacteria and the skin quality has been clarified, and the necessity of controlling skin microorganisms has been emphasized.

【0006】[0006]

【発明が解決しようとする課題】本発明者らは、健常皮
膚細菌叢について詳細に検討した結果、健全な美しい肌
では、好気的細菌の全部又は大部分を占める、表皮ブド
ウ球菌の数が、日々を通じて変動が少なく一定の菌数を
保つことを見いだした。
DISCLOSURE OF INVENTION Problems to be Solved by the Invention As a result of detailed examination of healthy skin flora, the number of Staphylococcus epidermidis, which accounts for all or most of aerobic bacteria in healthy beautiful skin, has been found. , It was found that there was little fluctuation throughout the day and a constant bacterial count was maintained.

【0007】そこで本発明者らは、皮膚上の細菌数を一
定に保つことにより、肌あれの防止および改善に寄与す
る可能性があると考え鋭意研究を重ねた結果、弱酸性で
抗菌性を有する生薬抽出物の連用が、皮膚常在菌の数を
効果的にコントロールすることを見いだし、本発明に至
ったのである。
[0007] Therefore, the inventors of the present invention have thought that it may contribute to the prevention and improvement of skin roughness by keeping the number of bacteria on the skin constant, and as a result, have conducted extensive studies and as a result, have weakly acidic and antibacterial properties. It was found that the continuous use of the herbal medicine extract effectively controls the number of skin indigenous bacteria, and the present invention has been completed.

【0008】[0008]

【課題を解決するための手段】すなわち本発明は、弱酸
性領域で殺菌、抗菌作用を有する下記植物から得られる
抽出物を、有効成分として1種又は2種以上を配合して
なる皮膚外用剤に関するものである。
[Means for Solving the Problems] That is, the present invention provides an external preparation for skin, which comprises, as an active ingredient, one or more kinds of extracts obtained from the following plants having bactericidal and antibacterial activities in a weakly acidic region. It is about.

【0009】本発明で用いられる弱酸性領域で殺菌、抗
菌作用を有する植物は、 (1) 甘茶 Hydrangeae Dulcis
Folium (2) 地楡 Sanguisorbae Rhiz
oma (3) 苦参 Sophorae Radix (4) 槐花 Sophorae Flos (5) 五味子 Schisandrae Fruct
us (6) カリン Pseudocydoniae Fr
uctus (7) 営実 Rosae Fructus (8) 夏枯草 Prunellae Spica (9) 芍薬 Paeoniae Radix (10) 防風 Saposhnikoviae Ra
dix (11) 牡丹皮 Moutan Cortex (12) 黄柏 Phellodendri Cort
ex (13) 黄連 Coptidis Rhizoma の13種類である。
Plants having a bactericidal and antibacterial action in the weakly acidic region used in the present invention are (1) Amanda Hydrangeae Dulcis
Folium (2) Jiang Sanguisorbae Rhiz
oma (3) Sophorae Radix (4) Sophora Flos (5) Sophorae Frost (5) Gomiko Schisandrae Fruct
us (6) Karin Pseudocydoniae Fr
uctus (7) Yomi fruit Rosae Fructus (8) Summer hay Prunellae Spica (9) Peony radish Paeoniae Radix (10) Windbreak Saposhnikoviae Ra
diox (11) peony skin Moutan Cortex (12) yellow oak Phellodendri Court
ex (13) Huanglian There are 13 types of Coptidis Rhizoma.

【0010】本発明に用いられるこれらの生薬抽出物
は、弱酸性条件で抗菌性を有しており、皮膚上に適用す
ることにより皮膚上微生物の数をコントロールし皮膚常
在菌の数や分布状態に起因する肌あれ、ニキビなどを改
善し、皮膚を健全な状態に保つことができる。
These crude drug extracts used in the present invention have antibacterial properties under mildly acidic conditions, and when applied on the skin, the number of microbes on the skin is controlled to control the number and distribution of skin-resident bacteria. It is possible to improve the skin roughness and acne caused by the condition and keep the skin in a healthy condition.

【0011】これらの抽出物は、作用する菌種の違いに
よりその抗菌力が異なり、またその抗菌力がpHの影響
を受けるものもある。従って、これらの抽出物を選択し
て使用することにより、皮膚細菌叢の個体差に対応でき
ることから、個人の肌質、肌状態に合うように効果的に
適用することも可能である。
[0011] These extracts have different antibacterial activity depending on the type of bacteria acting, and the antibacterial activity of some of these extracts is influenced by pH. Therefore, by selecting and using these extracts, it is possible to deal with individual differences in skin bacterial flora, and therefore, it is possible to effectively apply them in accordance with the skin quality and skin condition of an individual.

【0012】本発明では、前記植物の生薬、すなわち前
記植物の全体または一部分(例えば、全草、葉、根、根
茎、茎、根皮、花)を簡単に加工処理(例えば、乾燥、
切断、粉末化)したもの、またはその抽出物を用いる。
In the present invention, the herbal medicine of the plant, that is, the whole or part of the plant (eg, whole plant, leaf, root, rhizome, stem, root bark, flower) is simply processed (eg, dried,
Cut, powdered) or its extract is used.

【0013】本発明に用いる抽出物は、抽出したままの
溶液を用いても、溶媒を濃縮したエキスを用いても良い
し、溶媒を留去した粉末あるいは粘性のある物質を用い
ても良く、またそれらの希釈液を用いることもできる。
The extract used in the present invention may be an as-extracted solution, an extract obtained by concentrating the solvent, or a powder obtained by distilling the solvent or a viscous substance, Also, a diluted solution thereof can be used.

【0014】本発明で用いる生薬抽出物の製造方法とし
ては、上記植物または生薬乾燥物を水もしくは有機溶媒
(石油エーテル、シクロヘキサン、四塩化炭素、トルエ
ン、ベンゼン、ジクロロメタン、クロロホルム、エーテ
ル、酢酸エチル、ブタノール、アセトン、n−プロパノ
ール、エタノール、メタノール、ピリジン、ポリエチレ
ングリコール、プロピレングリコール、ブチレングリコ
ールなど)あるいはそれらを一定の比率で混合した溶
媒、たとえば含水アルコール等を用いる。好ましくは、
エタノール、水、ベンゼン、ブチレングリコール、含水
アルコール等が望ましい。抽出条件は一般的に植物抽出
に用いられる条件ならば特に制限はない。
As the method for producing the herbal medicine extract used in the present invention, the above-mentioned plant or herbal medicine dried product is treated with water or an organic solvent (petroleum ether, cyclohexane, carbon tetrachloride, toluene, benzene, dichloromethane, chloroform, ether, ethyl acetate, Butanol, acetone, n-propanol, ethanol, methanol, pyridine, polyethylene glycol, propylene glycol, butylene glycol, etc.) or a solvent in which these are mixed at a constant ratio, for example, hydrous alcohol or the like is used. Preferably,
Ethanol, water, benzene, butylene glycol, hydroalcohol and the like are preferable. The extraction conditions are not particularly limited as long as they are generally used for plant extraction.

【0015】本発明の皮膚外用剤の剤型は任意であり、
たとえば化粧水、クリーム、乳液、パック等の剤型をと
ることができ、製造工程の任意の段階に、任意の量配合
することができる。本発明の皮膚外用剤は前記の必須成
分の他に、必要に応じて本発明の効果を損なわない範囲
内で、化粧品、医薬部外品、医薬品等に一般的に用いら
れる各種成分、水性成分、油成分、保湿剤、増粘剤、防
腐剤、酸化防止剤、香料、色剤、薬剤等を配合すること
ができる。配合量は、乾燥残分量として、0.005〜
10重量%含有しているのが望ましく、さらに好ましく
は、0.05%〜5重量%の含有が皮膚上細菌に対す
る、顕著な効果を示し適当である。
The dosage form of the external preparation for skin of the present invention is arbitrary,
For example, a dosage form such as lotion, cream, emulsion, pack, or the like can be used, and can be blended in any amount at any stage of the production process. The external preparation for skin of the present invention includes, in addition to the above-mentioned essential components, various components generally used in cosmetics, quasi-drugs, pharmaceuticals, etc., and an aqueous component within a range that does not impair the effects of the present invention as necessary. An oil component, a moisturizer, a thickener, an antiseptic, an antioxidant, a fragrance, a coloring agent, a drug and the like can be added. The blending amount is 0.005 as the dry residue amount.
It is desirable to contain 10% by weight, and more preferably 0.05% to 5% by weight is suitable because it shows a remarkable effect on bacteria on the skin.

【0016】[0016]

【発明の効果】本発明の皮膚外用剤は肌あれまたはニキ
ビの予防、治療及び処置に有効である。
The external preparation for skin of the present invention is effective for the prevention, treatment and treatment of rough skin or acne.

【実施例】次に実施例をあげて本発明を更に詳しく説明
する。しかしながら、本発明の範囲を以下に示す実施例
に限定するものではない。なお、以下の例において、配
合量は重量%で示す。
The present invention will be described in more detail with reference to the following examples. However, the scope of the present invention is not limited to the examples shown below. In addition, in the following examples, the compounding amount is shown by weight%.

【0017】(製造例1) 各生薬の乾燥末を、10倍
量のエタノールで室温7日間抽出後濾過し、減圧濃縮に
よりエタノールを留去し抽出物を得た。
(Production Example 1) The dried powder of each crude drug was extracted with 10 volumes of ethanol at room temperature for 7 days, filtered and concentrated under reduced pressure to remove ethanol to obtain an extract.

【0018】(製造例2) 各生薬の乾燥末を、5倍量
の1,3−ブチレングレリコールで抽出後濾過し、抽出
物を得た。
(Production Example 2) The dried powder of each crude drug was extracted with 5-fold amount of 1,3-butylene grelicol and then filtered to obtain an extract.

【0019】(実施例1) 各生薬抽出物の弱酸性条件
下での種々の細菌に対する抗菌性を、ハートインヒュー
ジョン寒天培地(日水製薬製)を用いた寒天平板拡散法
で測定した。製造例1の抽出物をエタノールで10倍量
にし、その0.05mlを8mm径の濾紙ディスクに浸みこ
ませ、被験菌を接種分散させた寒天平板上に密着させ、
30℃、24時間培養した。培養終了時に濾紙周囲の菌
の発育が阻止されている透明帯(発育阻止帯)の直径を
求めた。
Example 1 The antibacterial activity of each crude drug extract against various bacteria under mildly acidic conditions was measured by an agar plate diffusion method using a heart infusion agar medium (manufactured by Nissui Pharmaceutical Co., Ltd.). The extract of Production Example 1 was made 10-fold volume with ethanol, and 0.05 ml thereof was soaked in a filter paper disk having a diameter of 8 mm, and closely contacted with the agar plate on which the test bacterium was inoculated and dispersed.
It was cultured at 30 ° C. for 24 hours. At the end of culturing, the diameter of the transparent zone (growth inhibition zone) in which the growth of bacteria around the filter paper was inhibited was determined.

【0020】結果を表1に示した。スタフィロコッカス
属細菌2株はpH5.5で、ミクロコッカス ルテウス
(Micrococcus luteus)はpH6.
0の培地上での阻止円の大きさを示している。
The results are shown in Table 1. Two Staphylococcus strains have a pH of 5.5, and Micrococcus luteus has a pH of 6.
The size of the inhibition circle on medium 0 is shown.

【0021】[0021]

【表1】 [Table 1]

【0022】(実施例2) 各抽出物のスタフィロコッ
カス エピデルミディスに対する生育阻害率を測定し
た。pH5.5およびpH7.2に調整したハートイン
ヒュージョン培地(日水製薬製)に実施例1で使用した
生薬エタノール抽出物の希釈液を0.2%になるように
添加し、スタフィロコッカス エピデルミディス AT
CC 14990を接種し30℃、24時間培養後の生
菌数を測定した。生育阻害率の算出は次に示す計算式で
算出した。結果は表2に示す通りである。
Example 2 The growth inhibition rate of each extract against Staphylococcus epidermidis was measured. To a heart infusion medium (manufactured by Nissui Pharmaceutical Co., Ltd.) adjusted to pH 5.5 and pH 7.2, the diluted solution of the crude drug ethanol extract used in Example 1 was added to 0.2%, and Staphylococcus epidermidis was added. AT
After inoculating CC 14990 and culturing at 30 ° C. for 24 hours, the viable cell count was measured. The growth inhibition rate was calculated by the following formula. The results are shown in Table 2.

【0023】[0023]

【数1】 [Equation 1]

【0024】[0024]

【表2】 [Table 2]

【0025】(実施例3) 化粧水(Example 3) Lotion

【0026】[0026]

【表3】 [Table 3]

【0027】上記成分(1)に(4)(5)(6)を室
温にて混合溶解させ、(2)(3)(7)を攪拌添加し
て化粧水を得た。
To the component (1), (4), (5) and (6) were mixed and dissolved at room temperature, and (2), (3) and (7) were added with stirring to obtain a lotion.

【0028】(実施例4) クリーム(Example 4) Cream

【0029】[0029]

【表4】 [Table 4]

【0030】上記成分(2)〜(9)を混合加熱して7
5℃とする。これに上記処方(1)及び(10)〜(1
2)を同様に加熱して75℃としたものを加え、ホモミ
キサーで均一に乳化しO/Wクリームを得た。
The above components (2) to (9) are mixed and heated to 7
Set to 5 ° C. In addition, the above prescriptions (1) and (10) to (1
2) was heated in the same manner and heated to 75 ° C., and the mixture was uniformly emulsified with a homomixer to obtain an O / W cream.

【0031】(実施例5) パック(Example 5) Pack

【0032】[0032]

【表5】 [Table 5]

【0033】上記成分(9)に(4)(5)(7)を加
え攪拌溶解した後、(3)を加え70℃に加熱し溶解さ
せた。次に(6)に(1)(2)及び(8)を加えて溶
解したものを添加後、冷却しパックを得た。
After adding (4), (5) and (7) to the above component (9) with stirring and dissolving, (3) was added and heated to 70 ° C. to dissolve. Next, (1), (2) and (8) were added to and dissolved in (6), and the mixture was cooled to obtain a pack.

【0034】(実施例6) 乳液Example 6 Emulsion

【0035】[0035]

【表6】 [Table 6]

【0036】上記成分(1)〜(8)を混合し70℃で
加熱溶解させたものを、(11)〜(12)を混合後、
加熱し70℃にしたものに加え、ホモミキサーで均一に
乳化した。これを攪拌しながら(9)に溶解させた(1
0)〜(13)と(14)を添加し、良く混合しながら
30℃まで冷却し乳液を得た。
The above components (1) to (8) were mixed and heated and dissolved at 70 ° C. After mixing (11) to (12),
The mixture was heated to 70 ° C. and homogenized with a homomixer. This was dissolved in (9) with stirring (1
0) to (13) and (14) were added, and the mixture was cooled to 30 ° C. with good mixing to obtain an emulsion.

【0037】(実施例7) 皮膚上微生物に対する本発
明品の連続塗布効果を次のような方法で測定した。被験
者4人に対し洗顔後、右側の頬に実施例3に示した化粧
水1gを均一に噴霧し、左側の頬には実施例3の化粧水
に生薬抽出物を添加しない化粧水(比較例)を同様に噴
霧した。その後日常生活を行い、翌日に綿棒で頬1cm
四方から細菌を採取し、一般生菌数、耐塩性微生物数、
および嫌気性細菌数を測定し1日目とした。細菌を採取
した後洗顔し、以後同様に化粧水を噴霧し、翌日細菌を
採取する行程を8日目まで行い、生菌数の変動を測定し
た。
Example 7 The effect of continuous application of the product of the present invention on microorganisms on the skin was measured by the following method. After washing the face of four test subjects, 1 g of the lotion shown in Example 3 was uniformly sprayed on the right cheek, and the lotion of Example 3 was not added to the lotion of Example 3 on the left cheek (comparative example). ) Was similarly sprayed. After that, I had a daily life, and on the next day, swab 1 cm on the cheek.
Bacteria were collected from all sides, and the number of general viable bacteria, the number of salt-tolerant microorganisms,
And the number of anaerobic bacteria was measured and set as the first day. After collecting the bacteria, the face was washed, and then lotion was sprayed in the same manner, and the process of collecting the bacteria the next day was performed until the 8th day, and the fluctuation of the viable cell count was measured.

【0038】図1に実施例3の化粧水を適用した時の結
果を、図2にその比較例の結果を示した。抽出物配合の
化粧水を塗布した頬では、日数経過による生菌数の変動
が少なく、また個人差も小さかった。また、菌種に関し
ても、好気的細菌ではスタフィロコッカス属やミクロコ
ッカス属細菌のような耐塩性細菌の数が大部分を占める
ようになり、好気性細菌と嫌気性細菌の菌数の差も小さ
く、常在菌生態系の維持が強く保たれている。
FIG. 1 shows the results when the lotion of Example 3 was applied, and FIG. 2 shows the results of the comparative example. On the cheeks to which the lotion containing the extract was applied, the viable cell count did not fluctuate with the passage of days, and individual differences were also small. Regarding the bacterial species, the number of salt-tolerant bacteria such as Staphylococcus spp. And Micrococcus spp. Has become large in the aerobic bacteria, and the difference in the number of aerobic and anaerobic bacteria has occurred. Is small, and the maintenance of the indigenous bacterial ecosystem is strongly maintained.

【図面の簡単な説明】[Brief description of drawings]

【図1】 実施例3に示した化粧水を連続塗布した時の
ヒト皮膚上の細菌数の変化を示すグラフである。
FIG. 1 is a graph showing changes in the number of bacteria on human skin when continuous application of the lotion shown in Example 3 is performed.

【図2】 図1に対する比較例のグラフである。すなわ
ち、実施例3に示した化粧水に生薬抽出物を添加しない
化粧水を塗布した時のヒト皮膚上の細菌数の変化を示す
グラフである。
FIG. 2 is a graph of a comparative example with respect to FIG. That is, it is a graph showing changes in the number of bacteria on human skin when the lotion shown in Example 3 was applied with lotion without adding a herbal medicine extract.

───────────────────────────────────────────────────── フロントページの続き (51)Int.Cl.5 識別記号 庁内整理番号 FI 技術表示箇所 A61K 35/78 J 7822−4C K 7822−4C F 7822−4C N 7822−4C ADA C 7822−4C ADZ H 7822−4C ─────────────────────────────────────────────────── ─── Continuation of the front page (51) Int.Cl. 5 Identification code Internal reference number FI Technical display location A61K 35/78 J 7822-4C K 7822-4C F 7822-4C N 7822-4C ADA C 7822-4C ADZ H 7822-4C

Claims (1)

【特許請求の範囲】[Claims] 【請求項1】 甘茶、地楡、苦参、槐花、五味子、黄
柏、黄連、カリン、営実、夏枯草、芍薬、防風、牡丹皮
から選ばれる生薬抽出物の1種又は2種以上を含有する
ことを特徴とする皮膚外用剤。
1. One or more kinds of crude drug extracts selected from sweet green tea, ground peony, bitter ginseng, Sophora, schizandra, yellow oak, yellow ream, quince, corn, summer hay, peony, windbreak, peony skin. A skin external preparation characterized by containing.
JP5071296A 1993-03-30 1993-03-30 Skin external preparation Pending JPH06279256A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP5071296A JPH06279256A (en) 1993-03-30 1993-03-30 Skin external preparation

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP5071296A JPH06279256A (en) 1993-03-30 1993-03-30 Skin external preparation

Publications (1)

Publication Number Publication Date
JPH06279256A true JPH06279256A (en) 1994-10-04

Family

ID=13456569

Family Applications (1)

Application Number Title Priority Date Filing Date
JP5071296A Pending JPH06279256A (en) 1993-03-30 1993-03-30 Skin external preparation

Country Status (1)

Country Link
JP (1) JPH06279256A (en)

Cited By (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07324038A (en) * 1994-05-31 1995-12-12 Makoto Ito Antibacterial agent containing 'ouren'
JPH08283143A (en) * 1995-04-14 1996-10-29 Kose Corp Skin preparation for external use
JPH1045556A (en) * 1996-08-02 1998-02-17 Noevir Co Ltd Antimicrobial and low-irritant cosmetic
JPH1045557A (en) * 1996-08-02 1998-02-17 Noevir Co Ltd Antimicrobial and low-irritant cosmetic
JPH1045558A (en) * 1996-08-02 1998-02-17 Noevir Co Ltd Antimicrobial and low-irritant cosmetic
KR19990052470A (en) * 1997-12-22 1999-07-05 성재갑 Composition having a cotton solubility effect
JP2001226213A (en) * 1999-12-06 2001-08-21 Shiseido Co Ltd Selective antimicrobial composition
WO2003086435A1 (en) * 2002-04-15 2003-10-23 Tetsuo Santo Cleanser
WO2003061554A3 (en) * 2002-01-26 2003-11-13 Micro Science Tech Co Ltd Composition containing moutan root bark extract as active ingredient
KR100491746B1 (en) * 1997-06-02 2005-09-02 주식회사 엘지생활건강 Composition for prevention and treatment of acne containing P. oleracea extract
WO2005044289A3 (en) * 2003-11-07 2005-11-24 Cognis France Sas An extract of the fruit of schisandra chinensis and its pharmaceutical and cosmetic use
JP2008174529A (en) * 2007-01-22 2008-07-31 Naris Cosmetics Co Ltd Allergen inactivating agent, skin care preparation containing the same and allergen inactivating product
JP2010202604A (en) * 2009-03-04 2010-09-16 Kose Corp Agent for normalization of skin indigenous microorganism, method for normalization of skin indigenous microorganism and dermatological external preparation or cosmetic using the same, and process for their productions
KR20120052991A (en) * 2009-07-30 2012-05-24 라보라토이레즈 익스펜사이언스 Cosmetic composition for the treatment of acne comprising a peptide extract of schizandra
KR101435679B1 (en) * 2007-09-10 2014-09-01 주식회사 엘지생활건강 Composition for moisturizing and improving wrinkle on skin
JP2015534466A (en) * 2012-08-03 2015-12-03 イェソン イ Wet tissue containing yellow continuous hot water extract extracted under high temperature and high pressure conditions
WO2017146096A1 (en) * 2016-02-25 2017-08-31 久光製薬株式会社 Adhesive patch
JP2018002703A (en) * 2016-06-23 2018-01-11 御木本製薬株式会社 Psoriasin production promoter
JP2021516223A (en) * 2017-12-20 2021-07-01 ブイティー シーエム プティ リミテッドVt Cm Pty Ltd Genuine skin supplements and medicated compositions for acne

Cited By (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07324038A (en) * 1994-05-31 1995-12-12 Makoto Ito Antibacterial agent containing 'ouren'
JPH08283143A (en) * 1995-04-14 1996-10-29 Kose Corp Skin preparation for external use
JPH1045556A (en) * 1996-08-02 1998-02-17 Noevir Co Ltd Antimicrobial and low-irritant cosmetic
JPH1045557A (en) * 1996-08-02 1998-02-17 Noevir Co Ltd Antimicrobial and low-irritant cosmetic
JPH1045558A (en) * 1996-08-02 1998-02-17 Noevir Co Ltd Antimicrobial and low-irritant cosmetic
KR100491746B1 (en) * 1997-06-02 2005-09-02 주식회사 엘지생활건강 Composition for prevention and treatment of acne containing P. oleracea extract
KR19990052470A (en) * 1997-12-22 1999-07-05 성재갑 Composition having a cotton solubility effect
JP2001226213A (en) * 1999-12-06 2001-08-21 Shiseido Co Ltd Selective antimicrobial composition
WO2003061554A3 (en) * 2002-01-26 2003-11-13 Micro Science Tech Co Ltd Composition containing moutan root bark extract as active ingredient
WO2003086435A1 (en) * 2002-04-15 2003-10-23 Tetsuo Santo Cleanser
WO2005044289A3 (en) * 2003-11-07 2005-11-24 Cognis France Sas An extract of the fruit of schisandra chinensis and its pharmaceutical and cosmetic use
JP2008174529A (en) * 2007-01-22 2008-07-31 Naris Cosmetics Co Ltd Allergen inactivating agent, skin care preparation containing the same and allergen inactivating product
KR101435679B1 (en) * 2007-09-10 2014-09-01 주식회사 엘지생활건강 Composition for moisturizing and improving wrinkle on skin
JP2010202604A (en) * 2009-03-04 2010-09-16 Kose Corp Agent for normalization of skin indigenous microorganism, method for normalization of skin indigenous microorganism and dermatological external preparation or cosmetic using the same, and process for their productions
KR20120052991A (en) * 2009-07-30 2012-05-24 라보라토이레즈 익스펜사이언스 Cosmetic composition for the treatment of acne comprising a peptide extract of schizandra
JP2015534466A (en) * 2012-08-03 2015-12-03 イェソン イ Wet tissue containing yellow continuous hot water extract extracted under high temperature and high pressure conditions
WO2017146096A1 (en) * 2016-02-25 2017-08-31 久光製薬株式会社 Adhesive patch
KR20180099862A (en) * 2016-02-25 2018-09-05 히사미쓰 세이야꾸 가부시키가이샤 Patch
JP2018002703A (en) * 2016-06-23 2018-01-11 御木本製薬株式会社 Psoriasin production promoter
JP2021516223A (en) * 2017-12-20 2021-07-01 ブイティー シーエム プティ リミテッドVt Cm Pty Ltd Genuine skin supplements and medicated compositions for acne

Similar Documents

Publication Publication Date Title
US10675488B2 (en) Acne removing skin care product and preparation method thereof
JPH06279256A (en) Skin external preparation
KR101135172B1 (en) A composition for the prevention, improvement or treatment of acne vulgaris comprising the mixture of extract of Phellodendron amurense Rupr, Houttuynia cordata, Paeonia lactiflora Pall, Agrimonia pilosa Ledeb, and Glycyrrhiza uralensis Fisch as an effective ingredient
CN111202822A (en) Gynecological external antibacterial spray and preparation method thereof
CN110638728B (en) Skin care composition for removing acne and lightening acne marks and preparation method and application thereof
CN108785200B (en) Antibacterial, acne-removing and anti-wrinkle silver ion moisturizing mask liquid, mask and preparation method of mask
TW201622738A (en) Use of plectranthus amboinicus extract for preparing anti-acne composition
KR101292274B1 (en) Cosmetic composition for anti-wrinkle
KR101034405B1 (en) Antibiotic composition containing herbal medicine extracts
JP2019178170A (en) Use of patchouli extract in preparation of compositions with anti-microorganism effect
KR101398549B1 (en) A composition for skin disease improvement comprising extracts or fractions of Eremochloa ophiuroides as an active ingredient
KR20160085011A (en) Cosmetic composition for alleviating sebum secretion comprising Carthamus tinctorius extract or mixture extract of Carthamus tinctorius and Areca catechu
CN113876852A (en) Antibacterial anti-inflammatory and antiallergic composition as well as preparation method and application thereof
CN113925907A (en) Antibacterial anti-inflammatory and antiallergic composition as well as preparation method and application thereof
CN107349165A (en) A kind of acne preventing and treating additive and its application
KR20180017974A (en) Cosmetic composition for preventing or treating acne comprising combined herbal extracts
KR101363028B1 (en) A cosmetic composition for the prevention, improvement or treatment of acne vulgaris comprising the mixture of extract of Melissa officinalis, Citrus bergamia, leaves of Mentha arvensis, Eclipta prostrata and Hovenia dulcis Thunb
KR101326679B1 (en) Skin external composition for treating or alleviating diaper rash containing zinc oxide stabilized by polyglyceryl-2 dipolyhydroxystearate
CN110721121A (en) A pasty facial mask containing Cannabis sativa extract and its preparation method
KR101914568B1 (en) Cosmetic Composition For A Alleviating Atopic Dermatitis And Pruritis Using By Bioconversion Of The Extracts and Method For Manufacturing the same
CN118370711B (en) Composition with bromhidrosis eliminating effect and application thereof
KR102381251B1 (en) Cosmetic composition for anti-oxidation, skin moisturizing, or improving of acne skin or skin trouble containing complex extract of Eriobotryae Folium
US10646425B1 (en) Cosmetic product for the skin comprising a combination of acetic acid and natural essential oils
KR101979658B1 (en) Manufacturing method of composition for hair-loss prevention and hair growth using shungite
Hayati et al. FORMULATION AND ANTIBACTERIAL ACTIVITY OF HERBAL TOOTHPASTE BASED ON ACEH TRADITIONAL MEDICINE